The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1705
Rezafungin (Rezzayo) for Invasive Candida Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rezafungin (Rezzayo) for Invasive Candida Infections
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rezafungin (Rezzayo) for Invasive Candida Infections
Article code: 1705d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.